Hims & Hers Health has begun offering a compounded version of Wego's tablet at an introductory price of $49 per month, about $100 less than Novo Nordisk's original[1][2]. This version contains the same active ingredient semaglutide as Wego from the Danish manufacturer Novo Nordisk[1][2]. Treatment can be tailored to patients who want to minimize side effects or prefer a tablet to an injectable form[1][2]. After the initial payment, patients with a five-month subscription will pay $99 per month, compared to $199 for Novo Nordisk[2]. Compounding is allowed in the US, that is, mixing ingredients in pharmacies to mimic the drug in other doses, and Hims & Hers already sells compounded versions of injectable Wegovy[1][2]. In September, the FDA warned Hims & Hers against misleading advertising of compound semaglutide, which is not approved[1]. Novo Nordisk terminated cooperation with Hims & Hers due to the sale of illegitimate copies of Wegova, which threaten patient safety[4][5]. Wegovy was approved by the FDA for the treatment of obesity in adults in March 2024[4].